Aktuelles & Neues von uns und unseren Kunden
Startschuss für unsere neue anti-Krisen-Kampagne: "Krise? na und!"
02. April 2009Mit Impulskraft gegen die Krise. medienimpuls, die Druckerei Späthling und 22markets präsentieren ihr neuestes Projekt - gemeinsam gegen die Krise!
Vieles ist neu bei medienimpuls
18. März 2009Krisenpreise für unsere treuen Kunden, ein neues Team, ein neuer Auftritt, neue Leistungen - doch unsere Leidenschaft ist ungebrochen!
YM Biosciences Announces First Patient Enrolled in Multi-National, Randomized, Double-Blind Trial of Nimotuzumab in Non-Small-Cell Lung Cancer
16. März 2009MISSISSAUGA, ON, March 16 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide,...
Ym Biosciences Announces Nimotuzumab Presentations to be Made at the 100TH Annual Meeting of the American Association for Cancer Research and European Society for Medical Oncology
13. März 2009"Data to be presented at the AACR and ESMO conferences, combined with rash being reported independent of the KRAS status of patients, are in sharp contrast to the dated speculation that toxicity is a marker for efficacy of...
Ym Biosciences Receives Clearance to Initiate Randomized Double-Blind Clinical Trials of Nimotuzumab in Lung Cancer and Brain Metastases From Lung Cancer
06. Januar 2009MISSISSAUGA, ON, Jan. 5 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide,...